(Q52925161)

9 May 2018

title

Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris. (English)

1 reference

9 May 2018

author name string

Alexander Nast

1

1 reference

9 May 2018

Ina B Kopp

2

1 reference

9 May 2018

Matthias Augustin

3

1 reference

9 May 2018

Kirstin-Benita Banditt

4

1 reference

9 May 2018

Wolf-Henning Boehncke

5

1 reference

9 May 2018

Markus Follmann

6

1 reference

9 May 2018

Markus Friedrich

7

1 reference

9 May 2018

Matthias Huber

8

1 reference

9 May 2018

Christina Kahl

9

1 reference

9 May 2018

Joachim Klaus

10

1 reference

9 May 2018

Joachim Koza

11

1 reference

9 May 2018

Inga Kreiselmaier

12

1 reference

9 May 2018

Johannes Mohr

13

1 reference

9 May 2018

Ulrich Mrowietz

14

1 reference

9 May 2018

Hans-Michael Ockenfels

15

1 reference

9 May 2018

Hans-Dieter Orzechowski

16

1 reference

9 May 2018

Jörg Prinz

17

1 reference

9 May 2018

Kristian Reich

18

1 reference

9 May 2018

Thomas Rosenbach

19

1 reference

9 May 2018

Stefanie Rosumeck

20

1 reference

9 May 2018

Martin Schlaeger

21

1 reference

9 May 2018

Gerhard Schmid-Ott

22

1 reference

9 May 2018

Michael Sebastian

23

1 reference

9 May 2018

Volker Streit

24

1 reference

9 May 2018

Tobias Weberschock

25

1 reference

9 May 2018

Berthold Rzany

26

1 reference

9 May 2018

Deutsche Dermatologische Gesellschaft (DDG)

27

1 reference

9 May 2018

Berufsverband Deutscher Dermatologen (BVDD)

28

1 reference

9 May 2018

publication date

1 July 2007

1 reference

9 May 2018

published in

JDDG

1 reference

9 May 2018

volume

5 Suppl 3

1 reference

9 May 2018

page(s)

1-119

1 reference

9 May 2018

Psoriasis in the community: prevalence, severity and patients' beliefs and attitudes towards the disease

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Psoriasis causes as much disability as other major medical diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Topical preparations for the treatment of psoriasis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

The role of salicylic acid in the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Tacrolimus ointment improves psoriasis in a microplaque assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Psoriasis of the glans penis in a child successfully treated with Elidel (pimecrolimus) cream

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Tacrolimus ointment causes inflammatory dendritic epidermal cell depletion but no Langerhans cell apoptosis in patients with atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Pimecrolimus does not affect the differentiation, maturation and function of human monocyte-derived dendritic cells, in contrast to corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Topical tacrolimus ointment combined with 6% salicylic acid gel for plaque psoriasis treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

An experimental ointment formulation of pimecrolimus is effective in psoriasis without occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Dithranol mediates pro-oxidative inhibition of polymorphonuclear leukocyte migration and lymphocyte proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Cyclosporin A, FK506 and dithranol after tyrosine-specific protein phosphorylation in HaCaT keratinocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

A novelliposomal formulation of dithranol for psoriasis: preliminary results

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Calcipotriol plus short-contact dithranol: a novel topical combination therapy for chronic plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Combining lesional short-contact dithranol therapy of psoriasis with a potent topical corticosteroid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Safety and efficacy of combined high-dose treatment with calcipotriol ointment and solution in patients with psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

A multicentre, parallel-group comparison of calcipotriol ointment and short-contact dithranol therapy in chronic plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Mometasone furoate 0.1%-salicylic acid 5% ointment versus mometasone furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis: a multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Calcitriol shows greater persistence of treatment effect than betamethasone dipropionate in topical psoriasis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Comparison of Hypothalamus-Pituitary-Adrenal Axis Suppression From Superpotent Topical Steroids by Standard Endocrine Function Testing and Gas Chromatographic Mass Spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

The use of 0.25% zinc pyrithione spray does not enhance the efficacy of clobetasol propionate 0.05% foam in the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Tar gel-phototherapy for psoriasis. Combined therapy with suberythemogenic doses of fluorescent sunlamp ultraviolet radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Investigator-masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. vs. mometasone furoate cream b.i.d. in the treatment of plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Strategies to optimize efficacy, duration of remission, and safety in the treatment of plaque psoriasis by using tazarotene in combination with a corticosteroid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

1alpha,25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical tria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Efficacy and safety of topical calcitriol (1,25-dihydroxyvitamin d3) for the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Calcitriol 3 microg g-1 ointment in combination with ultraviolet B phototherapy for the treatment of plaque psoriasis: results of a comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Randomized half-side comparison of narrowband UVB and trimethylpsoralen bath plus UVA treatments for psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Narrowband UVB and cream psoralen-UVA combination therapy for plaque-type psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Laser treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

A maintenance protocol for psoriasis plaques cleared by the 308 nm excimer laser

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Medium-dose 308-nm excimer laser for the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Efficacy of the 308-nm excimer laser for treatment of psoriasis: results of a multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Large increments in psoralen-ultraviolet A (PUVA) therapy are unsuitable for fair-skinned individuals with psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Psoralen-ultraviolet A therapy vs. psoralen-ultraviolet B therapy in the treatment of plaque-type psoriasis: our experience with fitzpatrick skin type IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

A comparison of the effect of narrow-band ultraviolet B in the treatment of psoriasis after salt-water baths and after 8-methoxypsoralen baths

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Influence of a mindfulness meditation-based stress reduction intervention on rates of skin clearing in patients with moderate to severe psoriasis undergoing phototherapy (UVB) and photochemotherapy (PUVA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Commercial tanning bed treatment is an effective psoriasis treatment: results from an uncontrolled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Comparison of photochemotherapy and dithranol in the treatment of chronic plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

A randomized, controlled clinical trial comparing photochemotherapy with dithranol in the initial treatment of chronic plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Tazarotene plus UVB phototherapy in the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Optimizing the frequency of outpatient short-contact dithranol treatment used in combination with broadband ultraviolet B for psoriasis: a randomized, within-patient controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

A randomized trial of etanercept as monotherapy for psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. OLP302 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Biological therapies in the systemic management of psoriasis: International Consensus Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

The mechanisms of action of cyclosporin A in the treatment of psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Body-weight-independent dosing of cyclosporine micro-emulsion and three times weekly maintenance regimen in severe psoriasis. A randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Relapse rates in moderately severe chronic psoriasis treated with cyclosporin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Multiple cutaneous squamous carcinoma in a psoriatic associated with ciclosporin, alcohol abuse and ultraviolet radiation exposure which were suppressed by acitretin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Combined mycophenolate mofetil and cyclosporin therapy for severe recalcitrant psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Fumaric acid esters in severe psoriasis, including experience of use in combination with other systemic modalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Dimethylfumarate for psoriasis: more than a dietary curiosity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Beneficial effects of fumarate therapy in psoriasis vulgaris patients coincide with downregulation of type 1 cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Inhibition of dendritic cell differentiation by fumaric acid esters

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Dimethylfumarate is a potent inducer of apoptosis in human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Topical calcipotriol plus oral fumaric acid is more effective and faster acting than oral fumaric acid monotherapy in the treatment of severe chronic plaque psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

[Efficacy and safety profile of fumaric acid esters in oral long-term therapy with severe treatment refractory psoriasis vulgaris. A study of 83 patients].

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Fumaric acid esters in the treatment of psoriasis: an Italian experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Methotrexate in psoriasis: consensus conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

The efficacy of methotrexate in psoriasis--a review of 40 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Methotrexate and histologic hepatic abnormalities: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Methotrexate induced liver cirrhosis. Studies including serial liver biopsies during continued treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Aminoterminal propeptide of type III procollagen in methotrexate-induced liver fibrosis and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Liver biopsies and methotrexate: a time for reconsideration?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Liver biopsy versus ultrasound in methotrexate-treated psoriasis: a decision analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Acitretin in combination with UVB or PUVA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Efficacy of Acitretin and Commercial Tanning Bed Therapy for Psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Balneotherapy in dermatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Climatotherapy of psoriasis and hypertension in elderly patients at the Dead-Sea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Levels of circulating CD8(+) T lymphocytes, natural killer cells, and eosinophils increase upon acute psychosocial stress in patients with atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

A Pilot Study of Hypnosis in the Treatment of Patients with Psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Narrowband UV-B (TL-01) phototherapy vs oral 8-methoxypsoralen psoralen-UV-A for the treatment of chronic plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

A combination therapy of calcipotriol cream and PUVA reduces the UVA dose and improves the response of psoriasis vulgaris.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

The Effect of Flash Lamp—Pulsed Dye Laser on Psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

A comparison of twice-weekly MPD-PUVA and three times-weekly skin typing-PUVA regimens for the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

Safety and efficacy study on etanercept in patients with plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2007.06172.X

10.1111/J.1610-0387.2007.06172.X

21 January 2018

Identifiers

DOI

1 reference

9 May 2018

1 reference

9 May 2018